Altimmune Statistics

Total Valuation

Altimmune has a market cap or net worth of $533.08 million. The enterprise value is $298.22 million.

Market Cap	533.08M
Enterprise Value	298.22M

Important Dates

The next estimated earnings date is Friday, May 8, 2026, before market open.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

Altimmune has 194.20 million shares outstanding. The number of shares has increased by 24.08% in one year.

Current Share Class	194.20M
Shares Outstanding	194.20M
Shares Change (YoY)	+24.08%
Shares Change (QoQ)	+12.52%
Owned by Insiders (%)	0.48%
Owned by Institutions (%)	32.18%
Float	193.27M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	13,072.93
Forward PS	n/a
PB Ratio	1.38
P/TBV Ratio	2.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	7,273.71
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 18.55, with a Debt / Equity ratio of 0.16.

Current Ratio	18.55
Quick Ratio	18.35
Debt / Equity	0.16
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-57.76

Financial Efficiency

Return on equity (ROE) is -50.57% and return on invested capital (ROIC) is -30.62%.

Return on Equity (ROE)	-50.57%
Return on Assets (ROA)	-28.17%
Return on Invested Capital (ROIC)	-30.62%
Return on Capital Employed (ROCE)	-35.67%
Weighted Average Cost of Capital (WACC)	5.95%
Revenue Per Employee	$719
Profits Per Employee	-$1.55M
Employee Count	57
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-681,000
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -45.66% in the last 52 weeks. The beta is 0.34, so Altimmune's price volatility has been lower than the market average.

Beta (5Y)	0.34
52-Week Price Change	-45.66%
50-Day Moving Average	3.60
200-Day Moving Average	4.05
Relative Strength Index (RSI)	30.98
Average Volume (20 Days)	4,665,109

Short Selling Information

The latest short interest is 28.73 million, so 14.80% of the outstanding shares have been sold short.

Short Interest	28.73M
Short Previous Month	29.25M
Short % of Shares Out	14.80%
Short % of Float	14.87%
Short Ratio (days to cover)	9.38

Income Statement

In the last 12 months, Altimmune had revenue of $41,000 and -$88.09 million in losses. Loss per share was -$1.00.

Revenue	41,000
Gross Profit	-66.39M
Operating Income	-94.49M
Pretax Income	-88.77M
Net Income	-88.09M
EBITDA	-94.38M
EBIT	-94.49M
Loss Per Share	-$1.00

Full Income Statement

Balance Sheet

The company has $273.46 million in cash and $35.69 million in debt, giving a net cash position of $237.77 million or $1.22 per share.

Cash & Cash Equivalents	273.46M
Total Debt	35.69M
Net Cash	237.77M
Net Cash Per Share	$1.22
Equity (Book Value)	224.89M
Book Value Per Share	2.03
Working Capital	263.20M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$67.54 million and capital expenditures -$11,000, giving a free cash flow of -$67.55 million.

Operating Cash Flow	-67.54M
Capital Expenditures	-11,000
Depreciation & Amortization	112,000
Net Borrowing	35.00M
Free Cash Flow	-67.55M
FCF Per Share	-$0.35

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-230,460.98%
Pretax Margin	-216,521.95%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Altimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-24.08%
Shareholder Yield	-24.08%
Earnings Yield	-16.44%
FCF Yield	-12.60%

Analyst Forecast

The average price target for Altimmune is $17.67, which is 543.72% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$17.67
Price Target Difference	543.72%
Analyst Consensus	Strong Buy
Analyst Count	6
Revenue Growth Forecast (5Y)	275.92%
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

The last stock split was on September 14, 2018. It was a reverse split with a ratio of 1:30.

Last Split Date	Sep 14, 2018
Split Type	Reverse
Split Ratio	1:30

Scores

Altimmune has an Altman Z-Score of 1.26 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.26
Piotroski F-Score	3